A new eyedrop has shown early success in delivering protective compounds to where they’re needed most in the eye, raising hopes for less invasive treatment of serious vision conditions.
The INTREPID study group, a team of 49 researchers from 30 academic and medical institutions, reports on sustained five-year benefits from subthalamic nucleus deep brain stimulation for Parkinson’s disease. They find improved motor function and daily living activities with a 28% reduction in anti-Parkinson’s medication.
Techsomed this week announced it received FDA 510(k) clearance to expand indications for its BioTraceIO360 software platform to include percutaneous ablation of soft tissue in the kidney.
The system leverages the company’s optical navigation system technology and the latest advancements in mixed reality.
Medtronic (NYSE: MDT)+
announced today that it received FDA approval for its Altaviva neuromodulation device.
Discover how turning organs into glass could revolutionize crucial transplant logistics.
CAESAREA, Israel, Sept. 18, 2025 /PRNewswire/ — IceCure Medical Ltd. (NASDAQ: ICCM) (“IceCure”, “IceCure Medical” or the “Company”), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent titled “Cryoprobe”.
J&J’s Shockwave Javelin intravascular lithotripsy catheter treats people with peripheral artery disease.
Mayo Clinic researchers have developed a genetic test that can help predict how people will respond to weight loss medications such as GLP-1s.
The investigational drug elinzanetant significantly reduces hot flashes and night sweats for postmenopausal women, a large, international clinical trial has found.